KDR and lung cancer: Cabozantinib, a small molecule multi-tyrosine kinase inhibitor against vascular endothelial growth factor receptor (VEGFR) and MET was used in patients with MET amplification, as it was shown to be effective in the treatment of lung cancer (D’Arcangelo et al. 2019).